Medistim ASA
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardiac and vascular surgery in the United States, Asia, Europe, and internationally. The company offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and TTFM in… Read more
Medistim ASA (MEDI) - Net Assets
Latest net assets as of June 2025: Nkr383.81 Million NOK
Based on the latest financial reports, Medistim ASA (MEDI) has net assets worth Nkr383.81 Million NOK as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr535.04 Million) and total liabilities (Nkr151.23 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr383.81 Million |
| % of Total Assets | 71.73% |
| Annual Growth Rate | 10.28% |
| 5-Year Change | 69.99% |
| 10-Year Change | 179.58% |
| Growth Volatility | 6.4 |
Medistim ASA - Net Assets Trend (2004–2024)
This chart illustrates how Medistim ASA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Medistim ASA (2004–2024)
The table below shows the annual net assets of Medistim ASA from 2004 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Nkr436.61 Million | +9.72% |
| 2023-12-31 | Nkr397.94 Million | +8.23% |
| 2022-12-31 | Nkr367.69 Million | +20.14% |
| 2021-12-31 | Nkr306.05 Million | +19.16% |
| 2020-12-31 | Nkr256.85 Million | +8.44% |
| 2019-12-31 | Nkr236.86 Million | +14.59% |
| 2018-12-31 | Nkr206.71 Million | +12.97% |
| 2017-12-31 | Nkr182.98 Million | +9.77% |
| 2016-12-31 | Nkr166.70 Million | +6.75% |
| 2015-12-31 | Nkr156.16 Million | +12.27% |
| 2014-12-31 | Nkr139.10 Million | +14.36% |
| 2013-12-31 | Nkr121.64 Million | +5.61% |
| 2012-12-31 | Nkr115.17 Million | +7.75% |
| 2011-12-31 | Nkr106.89 Million | -0.88% |
| 2010-12-31 | Nkr107.83 Million | +1.45% |
| 2009-12-31 | Nkr106.29 Million | +11.35% |
| 2008-12-31 | Nkr95.46 Million | +1.73% |
| 2007-12-31 | Nkr93.83 Million | +26.70% |
| 2006-12-31 | Nkr74.06 Million | +9.86% |
| 2005-12-31 | Nkr67.41 Million | +9.24% |
| 2004-12-31 | Nkr61.71 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Medistim ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 691.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr328.80 Million | 75.31% |
| Common Stock | Nkr4.58 Million | 1.05% |
| Other Components | Nkr103.23 Million | 23.64% |
| Total Equity | Nkr436.61 Million | 100.00% |
Medistim ASA Competitors by Market Cap
The table below lists competitors of Medistim ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inzone Group Co Ltd
SHG:600858
|
$229.27 Million |
|
ToolGen Inc.
KQ:199800
|
$229.27 Million |
|
Akcansa Cimento Sanayi ve Ticaret AS
IS:AKCNS
|
$229.30 Million |
|
BCPG Public Company Limited
BK:BCPG
|
$229.34 Million |
|
WIRTUALNA POL.BC ZY -05
F:9DE
|
$229.16 Million |
|
Hefei Gocom Information Technology Co Ltd
SHG:688367
|
$229.16 Million |
|
Alico Inc
NASDAQ:ALCO
|
$229.15 Million |
|
Lanzhou Foci Pharmaceutical Co Ltd
SHE:002644
|
$229.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Medistim ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 397,941,000 to 436,611,000, a change of 38,670,000 (9.7%).
- Net income of 103,832,000 contributed positively to equity growth.
- Dividend payments of 82,414,000 reduced retained earnings.
- Other factors increased equity by 17,252,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr103.83 Million | +23.78% |
| Dividends Paid | Nkr82.41 Million | -18.88% |
| Other Changes | Nkr17.25 Million | +3.95% |
| Total Change | Nkr- | 9.72% |
Book Value vs Market Value Analysis
This analysis compares Medistim ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.68x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 86.53x to 8.68x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2004-12-31 | Nkr2.39 | Nkr207.00 | x |
| 2005-12-31 | Nkr2.41 | Nkr207.00 | x |
| 2006-12-31 | Nkr2.44 | Nkr207.00 | x |
| 2007-12-31 | Nkr4.98 | Nkr207.00 | x |
| 2008-12-31 | Nkr5.09 | Nkr207.00 | x |
| 2009-12-31 | Nkr5.77 | Nkr207.00 | x |
| 2010-12-31 | Nkr5.89 | Nkr207.00 | x |
| 2011-12-31 | Nkr5.84 | Nkr207.00 | x |
| 2012-12-31 | Nkr6.31 | Nkr207.00 | x |
| 2013-12-31 | Nkr6.72 | Nkr207.00 | x |
| 2014-12-31 | Nkr7.68 | Nkr207.00 | x |
| 2015-12-31 | Nkr8.61 | Nkr207.00 | x |
| 2016-12-31 | Nkr9.18 | Nkr207.00 | x |
| 2017-12-31 | Nkr10.08 | Nkr207.00 | x |
| 2018-12-31 | Nkr11.37 | Nkr207.00 | x |
| 2019-12-31 | Nkr13.01 | Nkr207.00 | x |
| 2020-12-31 | Nkr14.08 | Nkr207.00 | x |
| 2021-12-31 | Nkr3.83 | Nkr207.00 | x |
| 2022-12-31 | Nkr20.15 | Nkr207.00 | x |
| 2023-12-31 | Nkr21.77 | Nkr207.00 | x |
| 2024-12-31 | Nkr23.84 | Nkr207.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Medistim ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 23.78%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 18.46%
- • Asset Turnover: 0.98x
- • Equity Multiplier: 1.32x
- Recent ROE (23.78%) is below the historical average (24.62%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | 30.26% | 22.38% | 0.98x | 1.37x | Nkr19.01 Million |
| 2008 | 14.18% | 9.65% | 0.96x | 1.52x | Nkr3.99 Million |
| 2009 | 26.22% | 17.77% | 1.08x | 1.37x | Nkr17.24 Million |
| 2010 | 17.30% | 11.90% | 1.07x | 1.35x | Nkr7.87 Million |
| 2011 | 14.49% | 9.70% | 1.07x | 1.40x | Nkr4.80 Million |
| 2012 | 26.26% | 16.62% | 1.20x | 1.32x | Nkr18.73 Million |
| 2013 | 21.82% | 13.94% | 1.13x | 1.38x | Nkr14.37 Million |
| 2014 | 22.46% | 14.58% | 1.05x | 1.46x | Nkr17.34 Million |
| 2015 | 25.88% | 16.17% | 1.14x | 1.40x | Nkr24.81 Million |
| 2016 | 23.45% | 14.88% | 1.21x | 1.30x | Nkr22.43 Million |
| 2017 | 26.00% | 16.07% | 1.18x | 1.37x | Nkr29.28 Million |
| 2018 | 27.60% | 17.66% | 1.20x | 1.30x | Nkr36.38 Million |
| 2019 | 29.68% | 19.70% | 1.06x | 1.42x | Nkr46.62 Million |
| 2020 | 27.02% | 19.48% | 1.03x | 1.35x | Nkr43.70 Million |
| 2021 | 29.70% | 21.76% | 1.04x | 1.32x | Nkr60.29 Million |
| 2022 | 31.00% | 23.17% | 1.02x | 1.31x | Nkr77.20 Million |
| 2023 | 26.09% | 19.72% | 1.04x | 1.27x | Nkr64.03 Million |
| 2024 | 23.78% | 18.46% | 0.98x | 1.32x | Nkr60.17 Million |
Industry Comparison
This section compares Medistim ASA's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $62,615,036
- Average return on equity (ROE) among peers: -203.78%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Medistim ASA (MEDI) | Nkr383.81 Million | 30.26% | 0.39x | $229.18 Million |
| Gentian Diagnostics AS (GENT) | $174.77 Million | -14.19% | 0.21x | $40.48 Million |
| Lifecare AS (LIFE) | $1.69 Million | -444.70% | 0.35x | $407.52K |
| Observe Medical Asa (OBSRV) | $11.39 Million | -152.45% | 4.62x | $1.80 Million |